MarketCapExport financials
Pluristem Therapeutics (PSTI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Pluristem Therapeutics Financial Ratios 2026-2009 | PSTI
Brief overview of Pluristem Therapeutics 's financial ratios
The comparison uses the five latest available annual observations between 2020 and 2025.
The current valuation set is P/E 0.28x (median 0.25x), EV/EBITDA 0.06x (median 0.06x), P/S 4.89x (median 16.56x). The multiple basket looks neutral against its history, differing from median levels by roughly -0.1%.
End-period return metrics are ROE -3.4%, ROA 60.1%, ROCE -58.7%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
Valuation takeaway
Pluristem Therapeutics 's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.
Annual Financial Ratios Pluristem Therapeutics
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | -0.3 | 0.3 | 0.2 | -0.8 | -0.6 | -5.7 | -2.0 | -5.0 | -3.7 | -5.1 | -6.8 | -6.7 | -7.9 | -9.9 | -9.9 | - | - |
P/S |
- | 4.9 | 16.6 | 16.4 | 141.7 | - | 7239.4 | 1279.0 | 2604.6 | - | 41.4 | 439.5 | 477.6 | 247.6 | 204.8 | - | - | - |
EPS |
-2.4 | -3.6 | -4.0 | -6.2 | -1.3 | -1.8 | -1.6 | -2.9 | -2.5 | -3.2 | -0.3 | -0.3 | -0.4 | -0.4 | -0.3 | -0.3 | -0.1 | - |
EV (Enterprise Value) |
-3.53 M | 632 K | -1.39 M | -641 K | 23.4 M | -3.13 M | 168 M | 74.4 M | 132 M | 106 M | 119 M | 154 M | 188 M | 170 M | 147 M | 66.8 M | -1.58 M | -2.34 M |
EBITDA per Share |
-2.51 | -3.45 | -4.18 | -5.87 | -1.26 | -1.75 | -1.53 | -2.72 | -3 | -2.96 | -2.66 | -3.3 | -4.09 | -3.82 | -3.31 | -3.46 | -0.13 | - |
EV/EBITDA |
0.1 | -0.0 | 0.1 | 0.0 | -0.6 | 0.1 | -5.7 | -1.9 | -3.8 | -3.8 | -5.3 | -6.2 | -6.8 | -7.5 | -7.9 | -5.9 | 0.6 | - |
PEG |
- | -0.0 | 0.0 | 0.0 | 0.06 | 0.11 | -0.13 | 0.12 | -0.23 | 0.36 | -0.3 | -0.41 | 0.64 | 0.68 | -3.47 | -0.48 | - | - |
P/B |
- | 0.2 | 0.1 | 0.1 | 0.5 | 0.3 | 3.0 | 3.2 | 4.6 | 3.4 | 3.1 | 2.9 | 2.9 | 2.9 | 3.9 | 2.5 | - | - |
P/CF |
- | -0.4 | -0.3 | -0.2 | -0.9 | -0.9 | -6.3 | -2.3 | -6.0 | -4.7 | -5.8 | -7.8 | -8.7 | -7.9 | -30.8 | -15.9 | - | - |
ROE % |
103.41 | 330.06 | 22233.33 | 216.30 | -137.29 | -87.25 | -51.96 | -161.80 | -91.65 | -91.94 | -60.92 | -42.44 | -43.35 | -36.81 | -39.20 | -24.98 | -70.86 | - |
ROA % |
-95.75 | -58.38 | 54.00 | 56.87 | -60.59 | -53.31 | -44.49 | -112.77 | -67.06 | -74.10 | -50.60 | -36.21 | -36.38 | -30.97 | -31.20 | -23.57 | - | - |
ROCE % |
185.51 | -5866.67 | -74.47 | -63.02 | -70.39 | -61.72 | -51.22 | -153.47 | -110.91 | -87.23 | -58.06 | -40.77 | -41.80 | -35.62 | -35.88 | -25.26 | -70.94 | - |
Current Ratio |
- | - | - | - | - | - | 6.1 | 3.2 | 3.7 | 5.4 | 6.2 | 9.2 | 8.4 | 9.3 | 6.9 | 21.5 | - | - |
DSO |
- | - | - | 1.9 | 17.2 | - | 25550.0 | 9604.9 | 6183.1 | - | 318.1 | 2415.4 | 2179.4 | - | 172.3 | - | - | - |
DPO |
508.3 | 489.7 | 126655.0 | 72939.2 | - | - | - | 416282.5 | 595132.5 | - | 9873.2 | 91755.4 | 114975.0 | 51775.2 | - | - | - | - |
Operating Cycle |
- | - | - | 1.9 | 17.2 | - | - | 9604.9 | 6183.1 | - | 318.1 | 2415.4 | 2179.4 | - | - | - | - | - |
Cash Conversion Cycle |
-508.3 | -489.7 | -126655.0 | -72937.3 | 17.2 | - | - | -406677.6 | -588949.4 | - | -9555.2 | -89340.0 | -112795.6 | -51775.2 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Pluristem Therapeutics
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | -0.55 | -0.71 | -0.65 | -0.71 | -0.65 | - | -0.94 | -0.53 | -1.08 | - | -1.01 | -0.96 | -0.96 | - | -0.19 | -0.24 | -0.19 | -0.44 | -0.31 | -0.34 | -0.36 | -0.7 | -0.48 | -0.49 | -0.33 | -0.49 | -0.33 | -0.4 | -0.46 | -0.4 | -0.46 | -0.75 | -0.77 | - | -0.01 | -0.08 | -0.08 | -0.08 | -0.08 | -0.08 | -0.08 | -0.08 | -0.08 | -0.05 | -0.07 | -0.05 | -0.07 | -0.09 | -0.09 | -0.09 | -0.09 | -0.11 | -0.08 | -0.11 | -0.08 | -0.08 | -0.08 | -0.08 | -0.08 | -0.05 | -0.11 | -0.05 | -0.11 |
EBITDA per Share |
- | -0.64 | -0.69 | -0.69 | -0.69 | -0.69 | - | - | -0.88 | -0.94 | - | - | - | -1.03 | - | - | -0.2 | -0.21 | -0.41 | -0.32 | -0.34 | -0.35 | -0.67 | -0.48 | -0.51 | -0.33 | -0.48 | -0.33 | -0.4 | -0.44 | -0.35 | -0.44 | -0.72 | -0.74 | - | -0.08 | -0.08 | -0.07 | -0.07 | -0.07 | -0.08 | -0.07 | -0.07 | -0.07 | -0.05 | -0.06 | -0.04 | -0.06 | -0.09 | -0.07 | -0.08 | -0.07 | -0.11 | -0.07 | -0.1 | -0.07 | -0.08 | -0.08 | - | -0.09 | - | -0.1 | -0.05 | -0.1 |
ROE % |
126.11 | 170.90 | 192.57 | 285.18 | 335.02 | 9626.74 | 9575.24 | 9288.36 | 9076.83 | 8930.55 | -405.96 | -445.95 | -191.58 | -140.20 | -95.26 | -142.66 | -127.24 | -122.19 | -122.81 | -114.55 | -114.92 | -117.97 | -111.94 | -103.30 | -95.70 | -105.23 | -132.76 | -142.29 | -165.68 | -182.79 | -195.74 | -160.31 | -141.84 | -115.01 | -57.18 | -79.45 | -105.15 | -109.21 | -98.12 | -102.17 | -91.08 | -72.79 | -64.79 | -46.50 | -38.51 | -43.19 | -42.97 | -47.65 | -47.44 | -45.75 | -43.42 | -41.73 | -39.40 | -34.88 | -31.74 | -27.22 | -29.13 | -27.56 | -33.18 | -31.61 | -32.17 | -11.15 | -4.94 | -11.15 |
ROA % |
-60.05 | -81.44 | -77.52 | -72.56 | -64.77 | -59.98 | -42.61 | -54.41 | -49.11 | -53.09 | -36.49 | -36.49 | -50.04 | -48.48 | -37.34 | -58.26 | -57.17 | -57.10 | -60.51 | -63.51 | -66.28 | -76.83 | -77.58 | -72.82 | -70.53 | -72.13 | -83.63 | -84.81 | -94.66 | -104.77 | -107.31 | -90.53 | -86.13 | -74.26 | -45.82 | -67.74 | -83.85 | -85.92 | -77.79 | -70.26 | -64.35 | -50.95 | -44.97 | -36.39 | -31.25 | -34.88 | -34.40 | -37.02 | -36.39 | -35.08 | -33.08 | -34.46 | -33.44 | -5698.96 | -5696.60 | -5686.80 | -5688.26 | -13.34 | -17.45 | -21.77 | -23.11 | -9.01 | -4.33 | -9.76 |
ROCE % |
298.79 | 389.84 | 484.42 | 373.17 | 203.26 | 95.36 | -55.80 | -355.74 | -349.63 | -344.24 | -327.39 | -341.87 | -54.14 | -52.72 | -39.35 | -62.37 | -62.58 | -65.44 | -68.38 | -72.47 | -75.12 | -90.98 | -92.65 | -96.24 | -96.23 | -100.94 | -123.39 | -129.63 | -150.45 | -163.62 | -176.17 | -164.96 | -148.56 | -128.16 | -75.89 | -97.70 | -100.33 | -103.28 | -93.70 | -96.40 | -86.84 | -70.36 | -61.38 | -44.82 | -35.85 | -39.48 | -39.35 | -43.15 | -42.98 | -41.76 | -40.17 | -39.06 | -37.53 | -33.97 | -31.34 | -20.82 | -22.69 | -15.66 | -19.83 | -24.89 | -25.49 | -9.67 | -5.17 | -10.60 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 565.4 | - | 108.6 | 1083.6 | - | - | 179.8 | - | 1890.7 | - | - | 43.1 | - | - | 9.4 | 1013.4 | 56.1 | 888.0 | 292.5 | 1303.4 | 2173.7 | 1086.8 | - | 131.1 | 747.8 | 617.5 | 390.7 | 390.4 | 89701.8 | 151.8 | 96977.8 | 112.3 | 60.8 | - |
DPO |
- | 722.2 | 770.3 | 429.2 | 770.3 | 395.6 | - | 328.5 | 1414.4 | 757.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 171686.9 | - | - | 216581.9 | 117963.4 | 208141.2 | - | 95949.4 | 123050.6 | - | - | 76672.8 | - | 89698.8 | - | - | 2278.1 | - | - | 1566.3 | 72437.3 | 3074.3 | 88056.2 | 56381.1 | 89516.2 | 79045.3 | 93926.7 | 85029.8 | 86946.0 | 86292.1 | 43197.7 | 12922.5 | 12907.1 | 10412902.5 | 19329.8 | 14665178.6 | 20558.6 | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 565.4 | - | 108.6 | 1083.6 | - | - | 179.8 | - | 1890.7 | - | - | 43.1 | - | - | 9.4 | 1013.4 | 56.1 | 888.0 | 292.5 | 1303.4 | 2173.7 | 1086.8 | - | 131.1 | 747.8 | 617.5 | 390.7 | 390.4 | 89701.8 | 151.8 | 96977.8 | 112.3 | 60.8 | - |
Cash Conversion Cycle |
- | - | - | - | -770.3 | -395.6 | - | -328.5 | -1414.4 | -757.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -171686.9 | - | - | -216581.9 | -117963.4 | -207575.9 | - | -95840.8 | -121967.0 | - | - | -76493.1 | - | -87808.1 | - | - | -2235.0 | - | - | -1556.9 | -71423.9 | -3018.2 | -87168.2 | -56088.6 | -88212.8 | -76871.6 | -92839.8 | -85029.8 | -86814.9 | -85544.3 | -42580.2 | -12531.8 | -12516.7 | -10323200.7 | -19177.9 | -14568200.8 | -20446.3 | 60.8 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Pluristem Therapeutics , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
CEL-SCI Corporation
CVM
|
$ 1.62 | 4.52 % | $ 13 M |  USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
$ 13.19 | -0.57 % | $ 11 B |  India |
 |
Replimune Group
REPL
|
$ 11.72 | 2.63 % | $ 1.09 B | USA |
 |
Rigel Pharmaceuticals
RIGL
|
$ 48.88 | 1.6 % | $ 879 M | USA |
 |
Gilead Sciences
GILD
|
$ 153.57 | -1.88 % | $ 191 B | USA |
 |
Entera Bio Ltd.
ENTX
|
$ 3.05 | 0.99 % | $ 141 M |  Israel |
 |
Evogene Ltd.
EVGN
|
$ 0.37 | -0.32 % | $ 2.91 M | Israel |
 |
Fate Therapeutics
FATE
|
$ 2.07 | 0.49 % | $ 246 M | USA |
 |
Daré Bioscience
DARE
|
$ 0.69 | -0.15 % | $ 7.71 M | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
$ 65.72 | -0.14 % | $ 183 M | Israel |
 |
Silence Therapeutics plc
SLN
|
$ 19.67 | 0.31 % | $ 2.79 B |  Britain |
 |
Sanofi
SNY
|
$ 40.97 | -1.04 % | $ 50 B |  France |
 |
Anavex Life Sciences Corp.
AVXL
|
$ 1.36 | -2.21 % | $ 116 M | USA |
 |
Syros Pharmaceuticals
SYRS
|
- | -8.44 % | $ 3.4 M | USA |
 |
Spruce Biosciences
SPRB
|
$ 42.73 | 3.64 % | $ 32.8 M | USA |
 |
Spero Therapeutics
SPRO
|
$ 1.17 | -4.1 % | $ 65.5 M | USA |
 |
Sutro Biopharma
STRO
|
$ 10.79 | -6.5 % | $ 91.7 M | USA |
 |
Shattuck Labs
STTK
|
$ 5.58 | -4.45 % | $ 388 M | USA |
 |
China SXT Pharmaceuticals
SXTC
|
$ 0.07 | 11.79 % | $ 47.6 K |  China |
 |
Gossamer Bio
GOSS
|
$ 9.79 | 2.19 % | $ 2.24 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
$ 14.37 | -2.51 % | $ 12.3 B | China |
 |
Bio-Techne Corporation
TECH
|
$ 72.64 | 0.08 % | $ 11.3 B | USA |
 |
Tenax Therapeutics
TENX
|
$ 1.63 | 2.15 % | $ 63.9 M | USA |
 |
Gamida Cell Ltd.
GMDA
|
- | -18.25 % | $ 5.04 M | Israel |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
$ 40.62 | -0.56 % | $ 46.5 B | Israel |
 |
TG Therapeutics
TGTX
|
$ 53.2 | -2.44 % | $ 7.68 B | USA |
 |
Heron Therapeutics
HRTX
|
$ 0.34 | -4.43 % | $ 56.7 M | USA |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
$ 5.43 | -6.06 % | $ 46.2 M | USA |
 |
Trevi Therapeutics
TRVI
|
$ 12.77 | -0.47 % | $ 1.72 B | USA |
 |
Taysha Gene Therapies
TSHA
|
$ 4.12 | 0.24 % | $ 1.32 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.2 | -9.61 % | $ 9.14 M | Israel |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | USA |
 |
Innoviva
INVA
|
$ 20.91 | -1.74 % | $ 1.41 B | USA |
 |
Genmab A/S
GMAB
|
$ 39.57 | 1.28 % | $ 2.56 B |  Danmark |
 |
UroGen Pharma Ltd.
URGN
|
$ 35.48 | 1.34 % | $ 1.71 B | Israel |
 |
United Therapeutics Corporation
UTHR
|
$ 563.49 | 1.74 % | $ 25 B | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.4 | -5.27 % | $ 4.43 M | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | USA |
 |
Vericel Corporation
VCEL
|
$ 40.94 | 0.89 % | $ 2.06 B | USA |
 |
Veracyte
VCYT
|
$ 46.22 | 3.19 % | $ 3.63 B | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
$ 3.55 | -2.2 % | $ 575 M | USA |
 |
Vir Biotechnology
VIR
|
$ 10.57 | -1.58 % | $ 1.46 B | USA |
 |
Viking Therapeutics
VKTX
|
$ 26.38 | -1.24 % | $ 2.97 B | USA |
 |
Vanda Pharmaceuticals
VNDA
|
$ 4.01 | -3.84 % | $ 236 M | USA |
 |
Johnson & Johnson
JNJ
|
$ 257.78 | -0.6 % | $ 621 B | USA |
 |
Verrica Pharmaceuticals
VRCA
|
$ 3.63 | 4.61 % | $ 38.7 M | USA |
 |
Viridian Therapeutics
VRDN
|
$ 23.01 | 2.59 % | $ 2.34 B | USA |
 |
Verastem
VSTM
|
$ 9.21 | -1.39 % | $ 638 M | USA |
 |
VistaGen Therapeutics
VTGN
|
$ 0.19 | -2.12 % | $ 7.23 M | USA |